产品
编 号：F420845
分子式：C9H10Cl2N4
分子量：245.11
分子式：C9H10Cl2N4
分子量：245.11
产品类型
规格
价格
是否有货
结构图
CAS No: 66711-21-5
产品详情
生物活性：
Apraclonidine (ALO 2145 (free base)), a selective α2 and weak α1 receptor agonist activity, effectively low intraocular pressure (IOP) in human eyes. Apraclonidine hydrochloride is a topical ophthalmic solution.
体内研究：
Apraclonidine (ALO 2145 (free base))is effective in animal models of elevated IOP as well as glaucoma in humans. The ocular hypotensive effects of Apraclonidine are usually attributed to reduced aqueous humor synthesis and vasoconstrictor actions at the anterior segment branches of the ophthalmic artery. Apraclonidine (ALO 2145 (free base))(1.15%, single instillation) inhibits 98% of PGE2-induced aqueous flare elevationy.Animal Model:male rabbits
Dosage:1.15%
Administration:Apraclonidine (1.15%, single instillation)
Result:Inhibited PGE2-induced elevation of aqueous flare in pigmented rabbits.
体外研究：
Apraclonidine (ALO 2145 (free base)) is more commonly used topically for glaucoma, as it penetrates the cornea and blood-brain barrier to a lesser extent and, thus, has fewer adverse systemic effects.
Apraclonidine (ALO 2145 (free base)), a selective α2 and weak α1 receptor agonist activity, effectively low intraocular pressure (IOP) in human eyes. Apraclonidine hydrochloride is a topical ophthalmic solution.
体内研究：
Apraclonidine (ALO 2145 (free base))is effective in animal models of elevated IOP as well as glaucoma in humans. The ocular hypotensive effects of Apraclonidine are usually attributed to reduced aqueous humor synthesis and vasoconstrictor actions at the anterior segment branches of the ophthalmic artery. Apraclonidine (ALO 2145 (free base))(1.15%, single instillation) inhibits 98% of PGE2-induced aqueous flare elevationy.Animal Model:male rabbits
Dosage:1.15%
Administration:Apraclonidine (1.15%, single instillation)
Result:Inhibited PGE2-induced elevation of aqueous flare in pigmented rabbits.
体外研究：
Apraclonidine (ALO 2145 (free base)) is more commonly used topically for glaucoma, as it penetrates the cornea and blood-brain barrier to a lesser extent and, thus, has fewer adverse systemic effects.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备